Opinionated, data-backed coverage across all asset classes

Axsome Therapeutics projects $8B in peak sales for Auvelity following an Alzheimer’s agitation approval. The June launch marks a critical commercial test.

NCLH forecasts 2026 EBITDA up to $2.64B despite a 5% yield decline. Watch for booking stability as the firm balances cost-cutting against geopolitical headwinds.

Mouwasat Medical Services targets Q2 2026 profit growth as its Yanbu hospital scales. The firm eyes faster break-even timelines to drive margin expansion.